When did Vor Biopharma report Q4 2025 earnings?

Vor Biopharma (VOR) reported Q4 2025 earnings on March 30, 2026 before market open.

What were Vor Biopharma's Q4 2025 revenue and EPS?

Vor Biopharma reported diluted EPS of $82.04 for Q4 2025.

Did Vor Biopharma beat estimates in Q4 2025?

EPS beat the consensus estimate of $-1.14 by $83.18.

Where can I find Vor Biopharma's Q4 2025 SEC filings?

You can read the 8-K earnings release (0001193125-26-127609) and the 10-K periodic report (0001193125-26-130451) directly on SEC EDGAR. The filing index links above go to sec.gov.

Vor Biopharma VOR Q4 2025 Annual earnings

Reported March 30, 2026 · Before market open

Diluted EPS$82.04Beat by $83.18

EPS estimate-$1.14

Next report

Aug 11, 2026 (In 4 weeks)

EPS estimate-$0.69

Financials

Q4 2025

Income statement

See full

Operating income-$36.0M-14.8%

Balance sheet

See full

Cash & equivalents$396.5M+384%

Total debt$3.0M-90.6%

Total equity-$164.3M-70.0%

Total assets$464.1M+225%

Cash flow

See full

Operating cash flow-$22.8M+5.2%

CapEx$314.0K+336%

Free cash flow-$23.1M+4.2%

Valuation & ratios

Valuation

as of 12/31/25

See full

Market cap$286.59M+107%

Enterprise value-$106.89M-221%

Returns & leverage

See full

Current ratio18.2×+13.0×

Versus estimates

Diluted EPS

Q1 2026-$0.73Beat by $0.02

Q4 2025$82.04Beat by $83.18

Q3 2025-$3.33Miss by $0.27 Q2 2025-$43.60Miss by $32.20 Q1 2025-$0.26Miss by $0.01 Q4 2024-$0.44Miss by $0.10

Ask the moment Vor Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Vor Biopharma report Q4 2025 earnings?: Vor Biopharma (VOR) reported Q4 2025 earnings on March 30, 2026 before market open.
What were Vor Biopharma's Q4 2025 revenue and EPS?: Vor Biopharma reported diluted EPS of $82.04 for Q4 2025.
Did Vor Biopharma beat estimates in Q4 2025?: EPS beat the consensus estimate of $-1.14 by $83.18.
Where can I find Vor Biopharma's Q4 2025 SEC filings?: You can read the 8-K earnings release (0001193125-26-127609) and the 10-K periodic report (0001193125-26-130451) directly on SEC EDGAR. The filing index links above go to sec.gov.